Metabolism - Clinical and Experimental
Volume 44, Issue 11 , Pages 1410-1412 , November 1995

Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia

Received 27 July 1994 ,Accepted 8 March 1995.

References 

  1. Reihner E, Rudling M, Stahlberg D, et al.  Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990;323:224–228
  2. Ahlberg J, Angelin B, Einarsson K. Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: Relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment. J Lipid Res. 1981;22:410–422
  3. Cooper J, Geizeroua M, Oliver M. Clofibrate and gallstones. Lancet. 1975;1:1083
  4. Grundy SM, Mok HYI, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981;22:24–36
  5. Coronary Drug Project Research Group . Gallbladder diseases as a side effect of drugs. N Engl J Med. 1977;296:1185
  6. Duane WC, Hunninghake DB, Freeman ML, et al.  Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147–1150
  7. Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology. 1990;98:1572–1578
  8. van der Hoogerbrugge LN, de Rooy FWM, Jansen H, et al.  Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolemia. Gut. 1990;31:348–350
  9. Mazzella G, Parini P, Festi D, et al.  Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. Hepatology. 1992;15:1072–1078
  10. Hatsushika S, Tazuma S, Kajiyama G. Nucleation time and fatty acid composition of lecithin in human gallbladder bile. Scand J Gastroenterol. 1993;23:131–136
  11. Tazuma S, Hatsushika S, Aihara N, et al.  Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion. 1992;51:179–184
  12. Tazuma S, Hatsushika S, Yamashita G, et al.  Simultaneous microanalysis of biliary cholesterol, bile acids and fatty acids in lecithin using capillary column gas chromatography: An advantage to assess bile lithogenicity. J Chromatogr. 1994;653:1–7
  13. Carey MC. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res. 1978;19:945–955
  14. Freeman ML, Prigge WF, Hunninghake DB, et al.  Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy. J Lipid Res. 1988;29:839–841
  15. Okamoto S, Nakano K, Kosahara K, et al.  Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones. J Gastroenterol. 1994;29:47–55
  16. Demel RA, Geurts van Kessel WSM, van Deenen LLM. The properties of polyunsaturated lecithins in monolayers and liposomes and the interactions of these lecithins with cholesterol. Biochim Biophys Acta. 1972;266:26–40
  17. Cohen DE, Carey MC. Acyl chain unsaturation modulates distribution of lecithin molecular species between mixed micelles and vesicles in model bile. In: Implications for particle structure and metastable cholesterol solubilities. ed 3. J Lipid Res. 32:1991;p. 1291–1302
  18. Tao S, Tazuma S, Kajiyama G. Fatty acid composition of lecithin is a key factor in bile metastability in supersaturated model bile systems. Biochim Biophys Acta. 1993;1167:142–146
  19. Tazuma S, Ochi H, Teramen K, et al.  Degree of fatty acyl chain unsaturation in biliary lecithin dictates cholesterol nucleation and crystal growth. Biochim Biophys Acta. 1994;1215:74–78

PII: 0026-0495(95)90138-8

Metabolism - Clinical and Experimental
Volume 44, Issue 11 , Pages 1410-1412 , November 1995